Recce Pharmaceuticals Ltd (ASX: RCE)
Health Care · Pharmaceuticals · AU
AU$0.37
-1.35% today · -15.1% 1Y
Recce Pharmaceuticals Ltd (ASX: RCE) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $78.35M and employs 8 people.
Over the last twelve months the share price has lost 15.1%, trading between 0.35 and 0.73.
Tweenvest scores Recce Pharmaceuticals Ltd across four factors: quality 4/100, value 39/100. Its strongest factor is value.
RCE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $78.35M
- Revenue (TTM)
- $650.05K
- P/E
- —
- EPS
- -0.11
- Dividend yield
- —
- Beta (5Y)
- 0.39
- 52-week high
- AU$0.73
- 52-week low
- AU$0.35
- Avg volume (3M)
- —
- Shares outstanding
- 299.47M
- Employees
- 8
- Next earnings
- —
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The company's foremost developmental drug, RECCE 327, is intended to address blood infections and sepsis caused by E. coli and S. aureus bacteria, including their antibiotic-resistant variants. Additionally, Recce is progressing RECCE 529, a synthetic anti-infective targeting viral illnesses, and RECCE 435, another synthetic polymer anti-infective. Founded in 2007, the firm, which was initially named Recce Limited, officially became Recce Pharmaceuticals Ltd in November 2017. Its corporate headquarters are situated in Sydney, Australia.
- ISIN
- AU000000RCE5
- Founded
- 2007
- Listed since
- Jan 14, 2016
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.